trending Market Intelligence /marketintelligence/en/news-insights/trending/oB5ht0KAjqlthwMQE12IzA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

NeuBase to raise $9M to fund genetic diseases platform amid merger with Ohr

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

NeuBase to raise $9M to fund genetic diseases platform amid merger with Ohr

Privately held NeuBase Therapeutics Inc. has signed a $9 million financing agreement that will close prior to the completion of its merger with Ohr Pharmaceutical Inc.

Pittsburgh-based NeuBase said the funds will help advance its proprietary peptide-nucleic acid antisense oligonucleotide platform called PATrOL. The platform uses antisense technology and has the potential to treat rare genetic diseases. NeuBase is initially exploring its use in Huntington's disease, an inherited disease that causes the progressive breakdown of nerve cells in the brain, and myotonic dystrophy, an inherited condition characterized by progressive muscle wasting and weakness.

The financing will consist of $8.4 million in commitments to buy NeuBase common shares and conversion of $600,000 in convertible notes that were issued after the merger with Ohr was announced.

NeuBase said the oversubscribed financing includes institutional investors including Cyto Ventures, a life sciences-focused venture capital fund affiliated with NeuBase CEO and member of Ohr's board, Dietrich Stephan.